Objectives:The diagnosis of Bipolar II disorder (BD-II) is currently based on patients' description of symptoms and clinical behavioral observations.This study explored the possibility of miRNA in peripheral blood (serum) as a specific blood-based biomarker for BD-II.Methods: We developed six miRNA profiles using next-generation sequencing from samples taken from three randomly picked controls and patients with BD-II each from a total of 102 BD-II patients and 118 controls.We further selected six differential expression miRNA candidates in the first cohort (as training group) of 79 BD-II and 95 controls and examined them using realtime PCR.Results: We found that serum expression levels of miR-7-5p, miR-23b-3p, miR-142-3p, miR-221-5p, and miR-370-3p significantly increased in patients with BD-II compared with controls in the first cohort.The diagnostic power of identified miRNAs was analyzed using receiver-operating characteristic (ROC) curves; results revealed miR-7-5p (area under the curve [AUC], 0.728; p < 0.0001), miR142-3p (AUC: 0.896; p < 0.0001), miR-221-5p (AUC: 0.824; p < 0.0001), and miR-370-3p (AUC: 0.703; p < 0.0001) to be good biomarkers for diagnosis of BD-II.Support vector machine (SVM) measurements revealed that a combination of four miRNAs may further improve the diagnostic accuracy (AUC: 0.907).We further examined an independent testing group (BD-II, n = 20; control, n = 20); the diagnostic power reached fair for BD-II (specificity = 90% and sensitivity = 85%). Conclusion:We constructed miRNA panels using SVM, which may aid in the development of objective diagnostic tools for BD-II.